The product

Axira, a drug intelligence suite for regulated science

IP filings in progress Released module by module

Axira brings AI powered intelligence across the drug development lifecycle, from biological signal detection and multi-omic biomarker discovery through to clinical data intelligence, sample management, and drug target identification. Each capability is independently deployable and each is designed to work inside the data integrity and regulatory standards that govern serious pharmaceutical research.

M01 Signal detection A safety signal is easy to see once someone has found it and hard to see while it is still forming. Phase 1 · First release M02 Biomarker discovery Multi-omic data produces candidates faster than any team can qualify them. Phase 2 · In development M03 Clinical data intelligence Clinical teams rarely lack data. Phase 3 · Sequenced M04 Sample management A specimen whose chain of custody cannot be reconstructed is a specimen whose results cannot be defended. Phase 3 · Sequenced M05 Target identification Ranked target lists are easy to produce and hard to trust. Phase 3 · Sequenced

Where most platforms offer analytics, Axira offers an answer that is validated, explainable, and traceable to the source. Capabilities are listed in functional terms. Individual platform names will be published following intellectual property filings. Hover a capability to lift it out of the suite.

The suite M00

Five capabilities on one shared architecture. Each can be deployed on its own, or run together as the suite.

Release model

One module at a time.

Development commenced in May 2026, and modules are released in sequence rather than all at once. Each one arrives as a minimum lovable product, meaning a first version complete enough to run on real work rather than a demonstration, and each is independently deployable on the shared architecture.

Protected

Described openly, named later.

Intellectual property filings for all modules are in progress. What each capability does is stated across these pages in functional terms. Individual platform names and technical architecture will be published once those filings complete, and detail is shared before then under a non-disclosure agreement.

Access

Early access is by application.

Tell us where you work and which module matters to you, and we will come back with what we can share today.

Apply for early access →